A $6B CVR goes pfffft as the game clock runs out on a New Year's deadline for Bristol Myers' liso-cel application
The last seconds of 2020 have ticked away, draining the last of the sand in the hour glass along with any remaining hopes in a $6 billion dream.
That $9 CVR Celgene investors got from Bristol Myers — worth a $6 billion payout — is no more. The deadline for an approval of liso-cel came at the witching hour Thursday night, without any world from Bristol Myers about what had happened. Then, Friday morning, January 1, the pharma giant — which has been stonily silent aside from putting the ball in the FDA’s court — acknowledged that the jig was up.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.